Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL182243 | 0.98 | ALDH1A1 (0.61) | ALDH1A1KMT2AKDM4ERAB9ARXFP1 | |
| SCHEMBL12779155 | 0.98 | ALDH1A1 (0.61) | ALDH1A1KMT2AKDM4ERAB9ARXFP1 | |
| SCHEMBL272269 | 0.96 | ALDH1A1 (0.63) | ALDH1A1KMT2AKDM4ERAB9ARXFP1 | |
| SCHEMBL6694683 | 0.92 | ALDH1A1 (0.56) | ALDH1A1KMT2AKDM4ERAB9ARXFP1 | |
| SCHEMBL16121924 | 0.85 | ALDH1A1 (0.56) | ALDH1A1KMT2AKDM4ERAB9ARECQL | |
| SCHEMBL23782299 | 0.85 | KDM4E (0.54) | ALDH1A1KMT2AKDM4ERAB9A | |
| SCHEMBL26177824 | 0.85 | KDM4E (0.54) | ALDH1A1KMT2AKDM4ERAB9A | |
| SCHEMBL23782301 | 0.85 | KDM4E (0.54) | ALDH1A1KMT2AKDM4ERAB9A | |
| SCHEMBL2672312 | 0.84 | KMT2A (0.58) | ALDH1A1KMT2AKDM4ERAB9ARECQL | |
| SCHEMBL3490122 | 0.84 | ALDH1A1 (0.58) | ALDH1A1KMT2AKDM4ERAB9ARECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11090288-B2 | Pyrazole derivatives and their uses thereof | UNIVERSITY HEALTH NETWORK (CA) | 2021-08-17 | — | — | US | disclosed |
| US-20190022066-A1 | PYRAZOLE DERIVATIVES AND THEIR USES THEREOF | UNIVERSITY HEALTH NETWORK (CA) | 2019-01-24 | — | — | US | disclosed |
| EP-2970138-B1 | PYRAZOLE DERIVATIVES AND THEIR USES THEREOF | CANADIAN BLOOD SERVICES (CA) | 2019-01-16 | — | — | EP | disclosed |
| US-9796716-B2 | Selective inhibitors of Tec and Src protein kinase families | PHARMASCIENCE, INC. (CA) | 2017-10-24 | — | — | US | disclosed |
| US-9796716-B2 | Selective inhibitors of Tec and Src protein kinase families | PHARMASCIENCE, INC. (CA) | 2017-10-24 | — | — | US | disclosed |
| US-20160022640-A1 | PYRAZOLE DERIVATIVES AND THEIR USES THEREOF | CANADIAN BLOOD SERVICES (CA) | 2016-01-28 | — | — | US | disclosed |
| US-20150191473-A1 | PROTEIN KINASE INHIBITORS | PHARMASCIENCE, INC. (CA) | 2015-07-09 | — | — | US | disclosed |
| US-20150191473-A1 | PROTEIN KINASE INHIBITORS | PHARMASCIENCE, INC. (CA) | 2015-07-09 | — | — | US | disclosed |
| WO-2014138979-A1 | PYRAZOLE DERIVATIVES AND THEIR USES THEREOF | CANADIAN BLOOD SERVICES (CA) | 2014-09-18 | — | — | WO | disclosed |
| WO-2013177668-A1 | PROTEIN KINASE INHIBITORS | PHARMASCIENCE, INC. (CA) | 2013-12-05 | — | — | WO | disclosed |
| US-20080261965-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-10-23 | — | — | US | disclosed |
| US-20070232591-A1 | Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues | NEUROGEN CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-20070232591-A1 | Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues | NEUROGEN CORPORATION | 2007-10-04 | — | — | US | disclosed |
| WO-2007106349-A2 | PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES | NEUROGEN CORPORATION (US) | 2007-09-20 | — | — | WO | disclosed |
| US-20060252780-A1 | Fused pyrimidine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-11-09 | — | — | US | disclosed |
| EP-1637532-A1 | FUSED PYRIMIDINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004096811-A1 | PDE9 INHIBITORS FOR TREATING TYPE 2 DIABETES, METABOKIC SYNDROME, AND CARDIOVASCULAR DISEASE | PFIZER PRODUCTS INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| US-20040220186-A1 | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease | PFIZER INC. | 2004-11-04 | — | — | US | disclosed |
| US-5541187-A | HYPOTENSIVE AGENTS | STERLING WINTHROP INC. (US) | 1996-07-30 | — | — | US | disclosed |
| US-5294612-A | Hypotensive agents and cardiovascular disorders | STERLING WINTHROP INC. (US) | 1994-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252780-A1 | Fused pyrimidine derivatives | INSR, GPR119, NPY4R | ALDH1A1 3942/4885KMT2A 3727/4885KDM4E 1514/4885 |
| US-11090288-B2 | Pyrazole derivatives and their uses thereof | SSB, HLA-DRB1, U2AF1 | ALDH1A1 1195/4885KMT2A 3993/4885KDM4E 3392/4885 |
| US-20160022640-A1 | PYRAZOLE DERIVATIVES AND THEIR USES THEREOF | SSB, HLA-DRB1, U2AF1 | ALDH1A1 890/4885KMT2A 4118/4885KDM4E 3591/4885 |
| US-20070232591-A1 | Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues | HRH3, HRH4, HRH1 | ALDH1A1 1229/4885KMT2A 566/4885KDM4E 2634/4885 |
| US-20190022066-A1 | PYRAZOLE DERIVATIVES AND THEIR USES THEREOF | SSB, HLA-DRB1, U2AF1 | ALDH1A1 1195/4885KMT2A 3993/4885KDM4E 3392/4885 |
| US-20040220186-A1 | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease | PDE9A, PDE2A, PDE12 | ALDH1A1 474/4885KMT2A 2217/4885KDM4E 1745/4885 |
| US-20080261965-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | KIT, PRKACA, BRAF | ALDH1A1 2292/4885KMT2A 658/4885KDM4E 1040/4885 |
| US-20150191473-A1 | PROTEIN KINASE INHIBITORS | TEC, SRC, LCK | ALDH1A1 4521/4885KMT2A 1665/4885KDM4E 1338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.